Media headlines about KemPharm (NASDAQ:KMPH) have trended positive on Thursday, Alpha One Sentiment reports. Alpha One, a unit of Accern, ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Alpha One ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. KemPharm earned a media sentiment score of 0.31 on Alpha One’s scale. Alpha One also gave news coverage about the specialty pharmaceutical company an impact score of 0 out of 100, meaning that recent news coverage is extremely unlikely to have an impact on the company’s share price in the near future.

KemPharm (NASDAQ:KMPH) traded down 10.87% during midday trading on Thursday, hitting $4.10. The company had a trading volume of 56,258 shares. KemPharm has a 52 week low of $2.90 and a 52 week high of $18.75. The company’s market capitalization is $60.05 million. The stock has a 50 day moving average price of $4.35 and a 200 day moving average price of $3.89.

KemPharm (NASDAQ:KMPH) last issued its earnings results on Thursday, March 9th. The specialty pharmaceutical company reported ($0.68) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.70) by $0.02. Equities analysts forecast that KemPharm will post ($2.53) earnings per share for the current fiscal year.

KMPH has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded KemPharm from a “sell” rating to a “hold” rating in a research report on Tuesday, February 7th. Royal Bank of Canada reiterated an “outperform” rating and issued a $8.00 price objective on shares of KemPharm in a research report on Saturday, March 11th. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of KemPharm in a research report on Wednesday, March 22nd. Finally, Canaccord Genuity set a $7.00 price objective on KemPharm and gave the stock a “buy” rating in a research report on Sunday, March 12th.

TRADEMARK VIOLATION WARNING: “KemPharm (KMPH) Receives News Sentiment Rating of 0.31” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at

KemPharm Company Profile

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

5 Day Chart for NASDAQ:KMPH

Receive News & Ratings for KemPharm Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.